The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Identifieur interne : 001243 ( PubMed/Checkpoint ); précédent : 001242; suivant : 001244The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Auteurs : P. Damier [France] ; E C Hirsch ; Yves Agid [France] ; A M GraybielSource :
- Brain : a journal of neurology [ 0006-8950 ] ; 1999.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Calbindins, Dopamine (analysis), Dopamine (metabolism), Humans, Nerve Degeneration (pathology), Nerve Tissue Proteins (analysis), Neurons (cytology), Neurons (metabolism), Neurons (pathology), Parkinson Disease (metabolism), Parkinson Disease (pathology), Reference Values, S100 Calcium Binding Protein G (analysis), Substantia Nigra (cytology), Substantia Nigra (metabolism), Substantia Nigra (pathology), Tyrosine 3-Monooxygenase (analysis).
- MESH :
- chemical , analysis : Dopamine, Nerve Tissue Proteins, S100 Calcium Binding Protein G, Tyrosine 3-Monooxygenase.
- chemical , metabolism : Dopamine.
- chemical : Calbindins.
- cytology : Neurons, Substantia Nigra.
- metabolism : Neurons, Parkinson Disease, Substantia Nigra.
- pathology : Nerve Degeneration, Neurons, Parkinson Disease, Substantia Nigra.
- Aged, Aged, 80 and over, Humans, Reference Values.
Abstract
To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.
PubMed: 10430830
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:10430830Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France. cic.salpetriere@psl.ap-hop-paris.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author><name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A M" last="Graybiel">A M Graybiel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10430830</idno>
<idno type="pmid">10430830</idno>
<idno type="wicri:Area/PubMed/Corpus">001384</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001384</idno>
<idno type="wicri:Area/PubMed/Curation">001343</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001343</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001343</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001343</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France. cic.salpetriere@psl.ap-hop-paris.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author><name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A M" last="Graybiel">A M Graybiel</name>
</author>
</analytic>
<series><title level="j">Brain : a journal of neurology</title>
<idno type="ISSN">0006-8950</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Calbindins</term>
<term>Dopamine (analysis)</term>
<term>Dopamine (metabolism)</term>
<term>Humans</term>
<term>Nerve Degeneration (pathology)</term>
<term>Nerve Tissue Proteins (analysis)</term>
<term>Neurons (cytology)</term>
<term>Neurons (metabolism)</term>
<term>Neurons (pathology)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (pathology)</term>
<term>Reference Values</term>
<term>S100 Calcium Binding Protein G (analysis)</term>
<term>Substantia Nigra (cytology)</term>
<term>Substantia Nigra (metabolism)</term>
<term>Substantia Nigra (pathology)</term>
<term>Tyrosine 3-Monooxygenase (analysis)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine</term>
<term>Nerve Tissue Proteins</term>
<term>S100 Calcium Binding Protein G</term>
<term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calbindins</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neurons</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Nerve Degeneration</term>
<term>Neurons</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Humans</term>
<term>Reference Values</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10430830</PMID>
<DateCreated><Year>1999</Year>
<Month>09</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>09</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8950</ISSN>
<JournalIssue CitedMedium="Print"><Volume>122 ( Pt 8)</Volume>
<PubDate><Year>1999</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Brain : a journal of neurology</Title>
<ISOAbbreviation>Brain</ISOAbbreviation>
</Journal>
<ArticleTitle>The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>1437-48</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damier</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France. cic.salpetriere@psl.ap-hop-paris.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hirsch</LastName>
<ForeName>E C</ForeName>
<Initials>EC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agid</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Graybiel</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS25529</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Brain</MedlineTA>
<NlmUniqueID>0372537</NlmUniqueID>
<ISSNLinking>0006-8950</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064026">Calbindins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064030">S100 Calcium Binding Protein G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber>
<NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 1999 Aug;122 ( Pt 8):1401-2</RefSource>
<PMID Version="1">10430827</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064026" MajorTopicYN="N">Calbindins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064030" MajorTopicYN="N">S100 Calcium Binding Protein G</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10430830</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
<orgName><li>Hôpital de la Salpêtrière</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A M" last="Graybiel">A M Graybiel</name>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
</region>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001243 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001243 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:10430830 |texte= The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:10430830" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |